DekaBank Deutsche Girozentrale
CBAY

DekaBank Deutsche Girozentrale’s Cymabay Therapeutics CBAY Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24,000
Closed -$85K – 1500
2021
Q3 		$85K Hold
24,000
– – ﹤0.01% 1312
2021
Q2 		$104K Hold
24,000
– – ﹤0.01% 1325
2021
Q1 		$103K Hold
24,000
– – ﹤0.01% 1279
2020
Q4 		$135K Buy
+24,000
New +$182K ﹤0.01% 1241

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CBAY Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Cymabay Therapeutics (CBAY) in Q4 2021, closing a stake of 24,000 shares — an estimated $85K sold.

DekaBank Deutsche Girozentrale first reported a position in CBAY in Q4 2020 and held it in 4 quarters. The position peaked at $135K in Q4 2020. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2021.

  • DekaBank Deutsche Girozentrale reported no remaining Cymabay Therapeutics position as of Q4 2021 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 24,000 Cymabay Therapeutics shares in Q4 2021, an estimated $85K.
  • DekaBank Deutsche Girozentrale first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 4 quarters.
  • DekaBank Deutsche Girozentrale's Cymabay Therapeutics position peaked at $135K in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.